FIELD: medicine; bariatric surgery.
SUBSTANCE: invention can be used to assess the individual risk of bariatric surgery. The following risk factors are identified: the patient's age, the presence of gastric and/or duodenal ulcer, diabetes mellitus without insulin therapy, diabetes mellitus requiring insulin therapy, acute cerebrovascular accident (CVA) or transient ischemic attack (TIA) in history. The following is taken into account: body mass index, the presence of abdominal obesity, comorbidity in relation to the following diseases: hypertension, atherosclerosis of the brachiocephalic arteries (BCA), chronic heart failure (CHF), pulmonary hypertension, impaired respiratory function, obstructive sleep apnea syndrome requiring therapy with non-invasive artificial ventilation of the lungs (NIVL), varicose veins of the lower extremities, hyperuricemia, bleeding in history, taking drugs that increase the risk of bleeding: antiplatelet agents, non-steroidal anti-inflammatory drugs (NSAIDs), stable angina and/or myocardial infarction (MI), impaired liver function: chronic viral hepatitis, and/or cirrhosis of the liver, and/or a 3-fold increase in the upper limits of normal AST/ALT/APF, anemia: hemoglobin level <90 g/l, history of venous thromboembolic complications (VTEC), chronic kidney disease: GFR<75 ml/min, chronic kidney disease: GFR≤30 ml/min. The functional activity of the patient, the presence and duration of surgical interventions in history is determined. Each risk factor is assigned a score. With a score of 0–11, a low risk of bariatric surgery is determined. With a score of 12 or more, the risk is assessed as high.
EFFECT: invention makes it possible to assess the individual risk of open and laparoscopic bariatric operations, to carry out additional therapeutic measures to reduce them and significantly reduce the risk of complications of surgical treatment of obesity.
1 cl, 4 tbl, 2 ex
